Last updated: February 22, 2026
What is the drug identified by NDC 51660-0142?
NDC 51660-0142 corresponds to Trelegy Ellipta, a triple-combination inhaler containing fluticasone furoate, umeclidinium, and vilanterol. Manufactured by GlaxoSmithKline, it is used primarily for the maintenance treatment of airflow obstruction in COPD and asthma.
What is the current market landscape for Trelegy Ellipta?
Market Size and Penetration
- Worldwide COPD market: projected to reach $33.81 billion by 2028, with CAGR of 4.4% (Fortune Business Insights, 2022).
- U.S. COPD market: accounts for roughly 45% of global sales, estimated at $12 billion in 2022.
- Trelegy Ellipta’s market share: approximately 25% of the inhaled corticosteroid/long-acting beta-agonist (ICS/LABA) segment in the U.S.
Competitors
- Breo Ellipta (GSK/United Therapeutics): a combination of fluticasone, umeclidinium, vilanterol.
- Symbicort (AstraZeneca): ICS/LABA.
- Dulera (AstraZeneca): ICS/LABA.
- Spiriva (Boehringer Ingelheim): LAMA.
Trelegy commands a premium relative to some competitors, driven by its triple therapy formulation.
Key Market Drivers
- Increased COPD prevalence linked to aging populations.
- Rising adoption of inhaled therapies over oral medications.
- Favorable insurance coverage in the U.S.
- Expanding indications for asthma in eligible patient populations.
What are the key regulatory developments?
- FDA approval for Trelegy Ellipta in 2017.
- Prescribing guidelines increasingly favor triple inhaler therapies for moderate-to-severe COPD.
- Ongoing post-marketing studies aim to expand indications.
What are current pricing trends?
Current Price Points
| Region |
Price per inhaler (approximate) |
Notes |
| U.S. |
$300–$350 |
Based on retail pharmacy pricing |
| Europe |
€25–€30 per inhaler |
Varies by country and insurance coverage |
| Canada |
CAD 450–$500 |
Under provincial formulary restrictions |
Reimbursement and Coverage Impact
- In the U.S., most commercial insurance plans cover Trelegy.
- Medicare Part D covers approximately 70% of prescriptions.
- Price remains stable in North America but varies internationally due to reimbursement policies.
What are the projections for future pricing?
Factors Influencing Price Trends
- Patent expiration: No immediate generic threat before 2030.
- Market competition: New entrants unlikely within the next 2–3 years.
- Regulatory channels: Potential for approvals of biosimilars or combination biosimilars, which could pressure price.
- Value-based arrangements: Increasing use of outcomes-based pricing may influence retail prices.
Predicted Price Trajectory (Next 3–5 Years)
| Year |
Expected Price Range (U.S.) |
Rationale |
| 2023 |
$300–$350 |
Stable amid steady demand, no generic competition. |
| 2024 |
$295–$340 |
Slight pressure from payer negotiations, stabilization. |
| 2025 |
$290–$330 |
Continued market stability, potential discounts from insurers. |
International prices may decline by 10–15%, dependent on policy adjustments and generic entry timelines.
What are the risks to price stability?
- Regulatory approval of biosimilars or generics.
- Policy changes favoring price reduction.
- Increased competition from new inhaler devices or therapies.
- Patent challenges delaying generic entry.
What is the business outlook?
- GSK’s focus on respiratory diseases sustains Trelegy’s market dominance.
- Strategic exclusivity until 2030 stabilizes pricing.
- Potential line extensions or formulation improvements could influence future value.
Key Takeaways
- Trelegy Ellipta is a dominant triple inhaler used in COPD and asthma, with a stable U.S. retail price around $300–$350 per inhaler.
- Market growth driven by aging populations and increased inhaler adoption sustains high demand.
- No immediate generic competition is expected before 2030.
- Pricing is likely to remain steady with slight decreases from payers, influenced by reimbursement dynamics.
- International prices vary, generally lower, subject to regional reimbursement policies.
FAQs
1. Will Trelegy Ellipta face significant price pressure from generics?
There are no approved generics or biosimilars in the near term. Patent protection extends until approximately 2030, limiting immediate generic competition.
2. How do insurance coverage policies affect Trelegy pricing?
Insurance plans, including Medicare Part D, heavily influence out-of-pocket costs. Favorable coverage sustains demand and price stability.
3. What factors could reduce Trelegy’s price in the future?
Regulatory approvals of biosimilars, increased competition, or policy reforms aimed at drug price reductions could lower retail prices.
4. What is the potential impact of new inhaler therapies on Trelegy?
Innovative device formulations or combination therapies may serve as substitutes, pressuring prices if they demonstrate superior efficacy or cost-effectiveness.
5. How does international pricing compare to the U.S.?
International prices are generally lower, with Europe and Canada seeing prices 20–30% below U.S. levels, driven by reimbursement systems and pricing regulations.
References
- Fortune Business Insights. (2022). Chronic obstructive pulmonary disease (COPD) drugs market size, share & trends analysis. https://www.fortunebusinessinsights.com/industry-reports/copd-drugs-market-107965
- U.S. Food & Drug Administration. (2017). FDA approves Trelegy Ellipta for COPD. https://www.fda.gov/
- IQVIA. (2022). National prescription audit: Inhaler market analysis. https://www.iqvia.com/
- European Medicines Agency. (2022). Marketing authorization for inhaled therapies. https://www.ema.europa.eu/
- Canadian Agency for Drugs and Technologies in Health. (2022). Respiratory medication review. https://www.cadth.ca/
